Clinical trials: Glucagon
ST Elevation Acute Myocardial Infarction
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
Remote ischemic conditioning (RIC) and intravenous exenatide administered immediately before primary angioplasty have been found to limit infarct size in patients with STEMI (ST segment elevation myocardial infarction), but the…
- Trial name
- COMBAT-MI (NCT02404376)
- Testing
- Exenatide, Remote Ischemic Conditioning (RIC)
- Where
- 6 sites in Spain
- Volunteers
- 378 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Metformin, Obesity, Abdominal
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.
- Conditions
- Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat
- Trial name
- NCT05779644
- Testing
- Liraglutide, Semaglutide, Metformin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Healthy Volunteers
The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants
This is a study to measure the effect that various doses of LY2409021 have on blood sugar levels and on the amount of glucose released by the liver, when glucagon is given to increase these.
- Trial name
- NCT01606423
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Residual Gastric Contents, Delayed Gastric Emptying
GLP-1 RA Cessation and Gastric Ultrasound Findings
This prospective observational study will evaluate the association between the time interval since the last dose of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and residual gastric contents before elective surgery.
- Trial name
- NCT07623148
- Testing
- GLP-1 RA Cessation Interval
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Wonkwang University Hospital
Obesity
Hydrogen-rich Water and Appetite in Obesity
The main goal of this study is to investigate how dihydrogen supplementation impacts body composition, appetite, quality of life specific to obesity, and levels of the hormone GLP-1 in men and women with obesity.
- Trial name
- HYDRAPPET (NCT06722326)
- Testing
- Dietary Supplement: Hydrogen-rich water, Dietary Supplement: Control water
- Where
- Serbia
- Volunteers
- 36 people
- Sponsor
- University of Novi Sad, Faculty of Sport and Physical Education
Colon Cancer
Glucagon Use in Colonoscopies
The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment…
- Trial name
- NCT02078726
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Francisco
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion (CSGI) or placebo.
- Trial name
- NCT03490942
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Xeris Pharmaceuticals
Osteoarthritis (OA) of the Knee
Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist
Studies have shown that obese patients undergoing total knee replacement (TKR) surgery face a higher risk of perioperative issues such as increased use of pain medication, surgical site infections, and the need for revision…
- Trial name
- NPO-OOPS-TKR (NCT06807970)
- Testing
- Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Control (Standard treatment)
- Where
- Hong Kong
- Volunteers
- 54 people
- Sponsor
- The University of Hong Kong
Type 2 Diabetes Mellitus
Diet Oil Induced Stimulation of GLP-1
Activation of G protein-coupled receptor GPR119 stimulates glucagon-like peptide-1 (GLP-1)release from the intestinal L-cells. Previously, administration of 2-oleyl-glycerol (2-OG) to humans significantly increased plasma GLP-1.
- Trial name
- NCT01453842
- Testing
- Diet oil, Olive oil, Carrot
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University of Copenhagen
Cystic Fibrosis-related Diabetes
Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes
The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children…
- Trial name
- NCT03258853
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Obesity With Diabetes, Overweight With Diabetes
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: Percent change in body weight Change in hemoglobin A1c (HbA1c)
- Trial name
- KaiNETIC-2 (NCT07284901)
- Testing
- Ribupatide
- Where
- 173 sites in United States, Argentina and 9 more
- Volunteers
- 1,270 people
- Sponsor
- Kailera
Obesity
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05111912
- Testing
- XW003, Saxenda
- Where
- Australia
- Volunteers
- 206 people
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Post-bariatric Surgery
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the…
- Trial name
- GLP-1 (NCT01803451)
- Testing
- exendin-(9-39), exendin -(9-39)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes, HIV Infections
The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism
The purpose of this study is to determine the mechanisms by which HIV protease inhibitors contribute to the development of diabetes in HIV-infected patients.
- Conditions
- Diabetes, HIV Infections, Insulin Resistance
- Trial name
- NCT00259727
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Obesity & Overweight, Mobility Disability
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
The primary objective of this study is to assess the effect of enobosarm on total body weight
- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Trial name
- PLATEAU (NCT07446998)
- Testing
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Where
- 13 sites in United States
- Volunteers
- 239 people
- Sponsor
- Veru Inc.
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
- Trial name
- NCT06500299
- Testing
- HDM1002 100 mg QD, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type1diabetes
Three Way Crossover Closed Loop Study With Xeris Glucagon
Closed-loop systems are an emerging technology that automate hormone delivery. They are quickly paving the way to revolutionize the treatment of type 1 diabetes.
- Trial name
- NCT03424044
- Testing
- Artificial Pancreas Controller in Dual Hormone Mode, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Oregon Health and Science University
Hypoglycemia, Diabetes Mellitus, Type 1
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare a needle-free treatment of hypoglycemia with nasal glucagon (study drug) to a marketed glucagon administered by the intramuscular (IM) route, in participants with type 1 diabetes mellitus…
- Trial name
- NCT03339453
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 2 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
The purpose of this study is to learn if giving multiple doses of a hormone called glucagon can cause a major decrease in liver glycogen (animal starch).
- Trial name
- NCT01986231
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Legacy Health System